Levonorgestrel-impregnated intrauterine device reduces occurrence of hyperplastic polyps: A population-based follow-up cohort study

Anticancer Research

Volumn 34, Issue 5, 2014, Pages 2319-2324

  Arnes, Marit ^a   Hvingel, Bodil ^b   Rbo, AnneØ ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Hyperplastic endometrial polyps; Intrauterine device; Levonorgestrel; Progestin therapy

Indexed keywords

GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; CONTRACEPTIVE AGENT;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; ENDOMETRIUM POLYP; FEMALE; FOLLOW UP; HUMAN; HYPERPLASTIC ENDOMETRIAL POLYP; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; POPULATION BASED CASE CONTROL STUDY; TUMOR CLASSIFICATION; WORLD HEALTH ORGANIZATION; ENDOMETRIUM HYPERPLASIA; HYPERPLASTIC ENDOMETRIAL POLYPS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; POLYP; PROGESTIN THERAPY; UTERUS DISEASE; VERY ELDERLY;

HYPERPLASTIC ENDOMETRIAL POLYPS; INTRAUTERINE DEVICE; LEVONORGESTREL; PROGESTIN THERAPY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; CONTRACEPTIVE AGENTS, FEMALE; ENDOMETRIAL HYPERPLASIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; POLYPS; UTERINE DISEASES;

EID: 84902994125     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Bernard JP, Rizk E, Camatte S, Robin F, Taurelle R and Lecuru F: Saline sonohysterography in the preoperative assessment of benign intrauterine disorders. Ultrasound Obstet Gynecol 17: 145-149, 2001.
2. Salim S, Won H, Nesbitt-Hawes E, Campbell N and Abbott J: Diagnosis and management of endometrial polyps: A critical review of the literature. J Minim Invasive Gynecol 18: 569-581, 2011.
3. Anastasiadis PG, Koutlaki NG, Skaphida PG, Galazios GC, Tsikouras PN and Liberis VA: Endometrial polyps: Prevalence, detection, and malignant potential in women with abnormal uterine bleeding. Eur J Gynaecol Oncol 21: 180-183, 2000.
4. Cohen JR, Luxman D, Sagi J, Yovel I, Wolman I and David MP: Sonohysterography for distinguishing endometrial thickening from endometrial polyps in postmenopausal bleeding. Ultrasound Obstet Gynecol 4: 227-230, 1994.
5. Lieng M, Qvigstad E, Sandvik L, Jorgensen H, Langebrekke A and Istre O: Hysteroscopic resection of symptomatic and asymptomatic endometrial polyps. J Minim Invasive Gynecol 14: 189-194, 2007.
6. Lieng M, Istre O and Qvigstad E: Treatment of endometrial polyps: A systematic review. Acta Obstet Gynecol Scand 89: 992-1002, 2010.
7. Bakour SH, Khan KS and Gupta JK: The risk of premalignant and malignant pathology in endometrial polyps. Acta Obstet Gynecol Scand 79: 317-320, 2000.
8. Cohen I: Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 94: 256-266, 2004.
9. Savelli L, De IP, Santini D, Rosati F, Ghi T, Pignotti E and Bovicelli L: Histopathologic features and risk factors for benignity, hyperplasia and cancer in endometrial polyps. Am J Obstet Gynecol 188: 927-931, 2003.
10. Lieng M, Istre O, Sandvik L and Qvigstad E: Prevalence, 1-year regression rate and clinical significance of asymptomatic endometrial polyps: Cross-sectional study. J Minim Invasive Gynecol 16: 465-471, 2009.
11. Randall TC and Kurman RJ: Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 90: 434-440, 1997.
12. Bese T, Vural A, Ozturk M, Dagistanli F, Demirkiran F, Tuncdemir M, Arvas M, Sanioglu and Kosebay D: The effect of long-term use of progesterone therapy on proliferation and apoptosis in simple endometrial hyperplasia without atypia. Int J Gynecol Cancer 16: 809-813, 2006.
13. Orbo A, Vereide AB, Arnes M, Pettersen I and Straume B: Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. BJOG 121:477-86, 2014. DOI: 10.1111/1471-528.12499.
14. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A and Gupta JK: Oral progestogens vs. levonorgestrel-releasing intrauterine system for endometrial hyperplasia: A systematic review and meta-Analysis. Am J Obstet Gynecol 203: 547-10, 2010.
15. Chin J, Konje JC and Hickey M: Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev CD007245, 2009.
16. Gardner FJ, Konje JC, Bell SC, Abrams KR, Brown LJ, Taylor DJ and Habiba M: Prevention of tamoxifen-induced endometrial polyps using a levonorgestrel-releasing intrauterine system long-term follow-up of a randomised control trial. Gynecol Oncol 114: 452-456, 2009.
17. Chan SS, Tam WH, Yeo W, Yu MM, Ng DP, Wong AW, Kwan WH and Yuen PM: A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG 114: 1510-1515, 2007.
18. Wong AW, Chan SS, Yeo W, Yu MY and Tam WH: Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: A randomized controlled trial. Obstet Gynecol 121: 943-950, 2013.
19. Baak JP, Nauta JJ, Wisse-Brekelmans EC and Bezemer PD: Architectural and nuclear morphometrical features together are more important prognosticators in endometrial hyperplasias than nuclear morphometrical features alone. J Pathol 154: 335-341, 1988.
20. Gallos ID, Krishan P, Shehmar M, Ganesan R and Gupta JK: Relapse of endometrial hyperplasia after conservative treatment: A cohort study with long-term follow-up. Hum Reprod 28: 1231-1236, 2013.
21. Kurman RJ, Kaminski PF and Norris HJ: The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 56: 403-412, 1985.
22. Orbo A, Baak JP, Kleivan I, Lysne S, Prytz PS, Broeckaert MA, Slappendel A and Tichelaar HJ: Computerised morphometrical analysis in endometrial hyperplasia for the prediction of cancer development. A long-term retrospective study from northern Norway. J Clin Pathol 53: 697-703, 2000.
23. Orbo A, Arnes M, Hancke C, Vereide AB, Pettersen I and Larsen K: Treatment results of endometrial hyperplasia after prospective D-score classification: A follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol 111: 68-73, 2008.
24. Kim KR, Peng R, Ro JY and Robboy SJ: A diagnostically useful histopathologic feature of endometrial polyp: The long axis of endometrial glands arranged parallel to surface epithelium. Am J Surg Pathol 28: 1057-1062, 2004.
25. Andersson JK and Rybo G: Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 97: 690-694, 1990.
26. Luukkainen T, Allonen H, Haukkamaa M, Holma P, Pyorala T, Terho J, Toivonen J, Batar I, Lampe L and Andersson K: Effective contraception with the levonorgestrel-releasing intrauterine device: 12-Month report of a European multicenter study. Contraception 36: 169-179, 1987.
27. Barrington JW and Bowen-Simpkins P: The levonorgestrel intrauterine system in the management of menorrhagia. Br J Obstet Gynaecol 104: 614-616, 1997.
28. Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ and Gupta JK: The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia-A long-term follow-up study. Eur J Obstet Gynecol Reprod Biol, 2008.
29. Wildemeersch D, Janssens D, Pylyser K, De WN, Verbeeck G, Dhont M and Tjalma W: Management of patients with non-Atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: Long-term follow-up. Maturitas 57: 210-213, 2007.
30. Vercellini P, Trespidi L, Bramante T, Panazza S, Mauro F and Crosignani PG: Gonadotropin-releasing hormone agonist treatment before hysteroscopic endometrial resection. Int J Gynaecol Obstet 45: 235-239, 1994.
31. Oguz S, Sargin A, Kelekci S, Aytan H, Tapisiz OL and Mollamahmutoglu L: The role of hormone replacement therapy in endometrial polyp formation. Maturitas 50: 231-236, 2005.
32. Preutthipan S and Herabutya Y: Hysteroscopic polypectomy in 240 premenopausal and postmenopausal women. Fertil Steril 83: 705-709, 2005.
33. Henriquez DD, van DH, Wolterbeek R and Jansen FW: Polypectomy in premenopausal women with abnormal uterine bleeding: Effectiveness of hysteroscopic removal. J Minim Invasive Gynecol 14: 59-63, 2007.
34. Svirsky R, Smorgick N, Rozowski U, Sagiv R, Feingold M, Halperin R and Pansky M: Can we rely on blind endometrial biopsy for detection of focal intrauterine pathology? Am J Obstet Gynecol 199: 115-113, 2008.
35. Exalto N, Stappers C, van Raamsdonk LA and Emanuel MH: Gel instillation sonohysterography: First experience with a new technique. Fertil Steril 87: 152-155, 2007.
36. Zaino RJ, Kauderer J, Trimble CL, Silverberg SG, Curtin JP, Lim PC and Gallup DG: Reproducibility of the diagnosis of atypical endometrial hyperplasia: A Gynecologic Oncology Group study. Cancer 106: 804-811, 2006.
37. Perez-Medina T, Bajo J, Huertas MA and Rubio A: Predicting atypia inside endometrial polyps. J Ultrasound Med 21: 125-128, 2002.
38. Vuento MH, Pirhonen JP, Makinen JI, Tyrkko JE, Laippala PJ, Gronroos M and Salmi TA: Screening for endometrial cancer in asymptomatic postmenopausal women with conventional and colour Doppler sonography. Br J Obstet Gynaecol 106: 14-20, 1999.
39. Orbo A, Kaino T, Arnes M, Larsen K, Pettersen I and Moe B: Prognostic markers for coexistent carcinoma in high-risk endometrial hyperplasia with negative D-score: significance of morphometry, hormone receptors and apoptosis for outcome prediction. Acta Obstet Gynecol Scand 88: 1234-1242, 2009.